Reports
Reports
The global connected drug delivery devices market size attained a value of USD 411.5 million in 2022 as the rapid surge in Bluetooth segment is expected to fuel the market growth. The market is anticipated to grow at a CAGR of 31.5% during the forecast period of 2023-2031 to attain a value of USD 4,812.8 million by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America holds a significant share in the connected drug delivery devices market on account of the speedy adoption of the latest technologies and high per capita healthcare expenditure. The rising awareness regarding the harmful effects that can result from non-compliance with drug therapy is likely to boost the market growth across the globe in the coming years.
The rapid acceptance of wireless & wi-fi-enabled remote drug delivery systems coupled with the surging consumption of integrated devices is expected to bolster the market growth in the region. Moreover, factors like the high presence of major market players like Phillips-Medisize Corporation and advanced applications of medical devices are expected to propel the market growth further in North America.
Specialised smart electronics, connected drug delivery devices support wireless connectivity and are used to dispense therapy that is patient administered. These devices are fully equipped with a wide range of sensors and other electronics. The various components work together to support multiple features, helping patents track their medication doses and overall adherence, while providing tools for further patient education.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By type, the connected drug delivery devices market is divided into:
Based on technology, the market is categorised into:
On the basis of end use, the market is segmented into:
The EMR report looks into the regional markets like Latin America, North America, Europe, Asia Pacific, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of technology, the Bluetooth segment is expected to fuel the market growth on account of its high usage in drug delivery devices coupled with technology advancements. The several benefits of Bluetooth usage like extended battery life, low costs, and easy availability are driving the segment growth in the connected drug delivery devices market.
Moreover, the rising popularity of electronic drug delivery devices, technological advancements, and the surging awareness of self-administered therapy are further anticipated to spur the market growth over the upcoming years. The increasing prevalence of diabetes along with the rising preference for homecare medication because of the surging product acceptance in homecare settings are expected to fuel the market growth.
The report presents a detailed analysis of the following key players in the global connected drug delivery devices market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the market. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2016-2022 |
Forecast Period | 2023-2031 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Product Type |
|
Breakup by Technology |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Supplier Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Connected Drug Delivery Devices Market Overview
3.1 Global Connected Drug Delivery Devices Market Historical Value (2016-2022)
3.2 Global Connected Drug Delivery Devices Market Forecast Value (2023-2031)
4 Global Connected Drug Delivery Devices Market Landscape
4.1 Global Connected Drug Delivery Devices Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Connected Drug Delivery Devices Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Technology
4.2.3 Analysis by End User
5 Global Connected Drug Delivery Devices Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Connected Drug Delivery Devices Market Segmentation
6.1 Global Connected Drug Delivery Devices Market by Product Type
6.1.1 Market Overview
6.1.2 Connected Sensors
6.1.3 Connected Inhaler Sensors
6.1.4 Connected Injection Sensors
6.1.5 Integrated Connected Devices
6.1.6 Integrated Inhalation Devices
6.1.7 Integrated Injection Devices
6.1.8 Others
6.2 Global Connected Drug Delivery Devices Market by Technology
6.2.1 Market Overview
6.2.2 Near Field Communication (NFC)
6.2.3 Bluetooth
6.2.4 Other
6.3 Global Connected Drug Delivery Devices Market by End User
6.3.1 Market Overview
6.3.2 Healthcare Providers
6.3.3 Homecare
6.3.4 Hospitals
6.3.5 Others
6.4 Global Connected Drug Delivery Devices Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Connected Drug Delivery Devices Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Connected Drug Delivery Devices Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Connected Drug Delivery Devices Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Connected Drug Delivery Devices Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Connected Drug Delivery Devices Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 BD
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 F. Hoffmann-La Roche Ltd.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Propeller Health
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 BioCorp
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Antares Pharma
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Novartis AG
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 3M
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Sulzer Ltd.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Gerresheimer AG
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Sanofi
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Johnson & Johnson Services, Inc.
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Bayer AG
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 GlaxoSmithKline plc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Novosanis
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 MEDMIX SYSTEMS AG
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Merck & Co., Inc.
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Pfizer Inc.
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
18 Global Connected Drug Delivery Devices Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
In 2022, the global market for connected drug delivery devices reached a value of USD 411.5 million.
The market is anticipated to grow at a CAGR of 31.5% during the forecast period of 2023-2031 to reach a value of USD 4812.8 million by 2031.
The major market drivers are the high per capita healthcare expenditure and increasing awareness about the harmful effects of non-compliance with drug therapy.
The key market trends include emerging economies along with surging cases of chronic diseases and the increasing advent of technology and wi-fi-enabled devices.
The major regions in the market as identified by the EMR report are North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
The various types of devices in the market include connected sensors, and integrated connected devices, among others.
The various technologies available in the market include near field communication (NFC), and Bluetooth, among others.
The primary end uses include hospitals and homecare.
The major players in the market are Adherium Limited, Propeller Health, Teva Pharmaceutical Industries Ltd., Phillips-Medisize (Molex, LLC), and Elcam Drug Delivery Devices, among others.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.